Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasPsychopharmacology — fitness to drive

Psych Vivas · Psychopharmacology — fitness to drive

Psychotropics, sedation and driving — consultant viva

Fellowship viva covering residual hypnotic impairment, crash epidemiology, illness vs drug effects, counselling, and licence-class standards.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
Examiner places cards: SDLP, zopiclone 7.5 mg, long-half-life BZD elderly, Thomas ~2×, Fournier concurrent, methylphenidate ADHD highway, commercial licence, alcohol co-use, document advice.

Opening (1–2 min)

Define fitness to drive as a clinical–functional judgment integrating illness severity, medication residual/psychomotor effects, substance co-use, and licence class — not a permanent ban on all psychotropics.[1][10]

Core probes and model points

1. Epidemiology cards

  • Thomas: BZD use ≈ doubles MVC risk in case-control synthesis.[2]
  • Hemmelgarn: long-half-life BZDs in the elderly raise crash risk.[3]
  • Gustavsen: zopiclone/zolpidem/flunitrazepam/nitrazepam prescription-linked accident risk.[5]
  • Dassanayake: meta-analytic synthesis across BZD, antidepressants, opioids.[9]
  • Fournier: concurrent BZD + antidepressant in older drivers.[8]

2. SDLP and residual hypnotics

Name SDLP as on-road weaving metric. Residual morning impairment after bedtime BZD hypnotics and zopiclone is experimentally robust; zopiclone is often a positive control for residual impairment — kill the myth that Z-drugs are driving-safe by class label alone.[1][4][5]

3. Illness versus tablet

Wingen: long-term SSRI/SNRI-treated depressed patients can still show on-road impairment vs controls — residual illness matters.[6] Verster/Roth: methylphenidate can reduce highway attention lapses in ADHD — treat the disorder.[7] Brunnauer synthesis: patient driving performance often improves as treatment stabilises non-sedating regimens.[10]

4. Counselling script (say it aloud)

Warn at initiation; temporary restriction during titration/acute illness; never combine with alcohol; reassess when stable; document understanding and review date; commercial licences need higher standards and often occupational clearance.[1][10]

5. Regional principles

State Austroads / DVLA / local US frameworks as living standards; do not invent mandatory reporting statutes from memory — principles first, then check current guidance.[1][10]

Rapid-fire pearls

  • Zopiclone ≠ automatic green light for morning commute.[4][5]
  • Alcohol multiplies sedative risk every time.[1][9]
  • Document or it did not happen medico-legally.[1]
  • Commercial ≠ private standard.[1][10]

Examiner traps

  • Claiming all antidepressants permanently unfit drivers.[6][10]
  • Ignoring near-miss history while debating product class labels.[1]
  • Clearing a truck driver on the same criteria as a private car user without occupational thought.[1][10]

References

  1. [1]Verster JC, Mets MA. Psychoactive medication and traffic safety Int J Environ Res Public Health, 2009.PMID 19440432
  2. [2]Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association Can Fam Physician, 1998.PMID 9585853
  3. [3]Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly JAMA, 1997.PMID 9207334
  4. [4]Verster JC, Veldhuijzen DS, Volkerts ER. Residual effects of sleep medication on driving ability Sleep Med Rev, 2004.PMID 15233958
  5. [5]Gustavsen I, Bramness JG, Skurtveit S, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam Sleep Med, 2008.PMID 18226959
  6. [6]Wingen M, Ramaekers JG, Schmitt JA. Driving impairment in depressed patients receiving long-term antidepressant treatment Psychopharmacology (Berl), 2006.PMID 16865389
  7. [7]Verster JC, Roth T. Methylphenidate significantly reduces lapses of attention during on-road highway driving in patients with ADHD J Psychopharmacol, 2014.PMID 24978156
  8. [8]Fournier JP, Wilchesky M, Patenaude V, et al. Concurrent Use of Benzodiazepines and Antidepressants and the Risk of Motor Vehicle Accident in Older Drivers: A Nested Case-Control Study CNS Drugs, 2015.PMID 26847674
  9. [9]Dassanayake T, Michie P, Carter G, et al. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence Drug Saf, 2011.PMID 21247221
  10. [10]Brunnauer A, Herpich F, Zwanzger P, et al. Driving Performance Under Treatment of Most Frequently Prescribed Drugs for Mental Disorders: A Systematic Review of Patient Studies Int J Neuropsychopharmacol, 2021.PMID 34038545